Actually, Idit, I don’t recall MNTA’s having cited any external “experts” to support its contention that generic Copaxone is approvable under the 505(j) pathway.
The press release Teva issued on Saturday (#msg-100823586) suggests to me that Teva’s corporate culture still needs a lot of work.
Market Data 
Markets 
AI
